絞り込み

16315

広告

A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.

著者 Fanola CL , Giugliano RP , Ruff CT , Trevisan M , Nordio F , Mercuri MF , Antman EM , Braunwald E
Eur Heart J.2017 Jan 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (70view , 0users)
  • このエントリーをはてなブックマークに追加

Full Text Sources

Miscellaneous

The choice between initiating a non-vitamin K antagonist oral anticoagulant (NOAC) and a vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) may be challenging. To assist in this decision, we developed a risk score to identify patients for whom a therapeutic benefit of NOACs over VKA is predicted.
PMID: 28064150 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード